How to Buy Protagonist Therapeutics Stock
Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies.
Protagonist Therapeutics stock last closed at $143.00, down 0.49% from the previous day, and has increased 130.13% in one year. It has overperformed other stocks in the Biotechnology industry by 1.52 percentage points. Protagonist Therapeutics stock is currently +130.83% from its 52-week low of $61.95, and -11.08% from its 52-week high of $160.81.
There are currently 64.71M PTGX shares outstanding. The market value of PTGX is $9.25B. In the last 24 hours, 1.82M PTGX shares were traded.
How to Buy Protagonist Therapeutics Stock
Not sure how to invest in Protagonist Therapeutics stock? Here's how.
- Figure out where to buy Protagonist Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you decide where to buy Protagonist Therapeutics stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Put funds into your investment account: Select your method of payment and add your info.
- Analyze Protagonist Therapeutics stock: The Protagonist Therapeutics ticker symbol is PTGX. Is Protagonist Therapeutics stock a good investment? Should you buy shares of PTGX? How do PTGX's underlying business fundamentals look? Do top analysts think Protagonist Therapeutics is a good buy? Why has PTGX's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if PTGX is a good stock to buy).
- Make your PTGX buy order: Decide if you will purchase PTGX shares at the current market price or use a limit order to purchase PTGX stock at a given price.
- Keep an eye on your PTGX investment: Create a watchlist to monitor your investment in Protagonist Therapeutics stock.
Step 1: Figure out where to buy Protagonist Therapeutics stock
You will need an online brokerage account to access the NASDAQ market and buy PTGX stock.
Our favorite brokerage: eToro
In our opinion, eToro is the best brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Real Estate, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro offers a community of more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected the best brokerage, you'll need to fill out some personal details so you can invest in PTGX stock today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to start your new trading account.
- Send your info by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you've finished signing up on investing apps, you can securely and quickly fund your account:
Watch the video below for more details depositing money into your new brokerage account.
Step 4: Analyze Protagonist Therapeutics stock
After you have selected the best place to buy Protagonist Therapeutics stock, it's absolutely critical to research their stock prior to investing, so you truly wrap your head around the risk as well as the opportunity.
Protagonist Therapeutics stock data
Fundamentals of Protagonist Therapeutics
WallStreetZen was built to help average investors do more accurate fundamental analysis quickly.
You can view all of the due diligence checks on PTGX's stock page.
Is PTGX stock undervalued?
Analysts use many financial metrics, analyses, models, and charts to gauge PTGX's fair value.
Using relative valuations metrics:
- PTGX could be overvalued based on its P/E ratio of 118.18x, relative to Biotechnology industry P/E ratio of 9.29x
- PTGX could be overvalued based on its P/B ratio of 11x, relative to Biotechnology industry P/B ratio of 5.28x
You can do more valuation analysis on PTGX's stock here.
A quick look at PTGX Financials
Signs that PTGX is financially healthy:
- PTGX profit margin has gone up from 24.9% to 29.4% in the past year.
- There are more short-term assets than short-term liabilities on the PTGX balance sheet.
- PTGX has a low debt to equity ratio of 0.05.
- Total PTGX debt is lower than 5 years ago, relative to shareholder equity.
- PTGX earnings of $84.34M is not enough to cover its interest payments.
- There are more short-term assets than long-term liabilities on the PTGX balance sheet.
- PTGX's operating cash flow of $131.20M allows it to safely service it's debt of $9.22M.
Is Protagonist Therapeutics stock a Buy, Hold, or Sell, according to analysts?
Out of 8 Wall Street analysts who give recommendations on PTGX, the consensus analyst rating on PTGX is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
Most Recent PTGX Analyst Forecasts
Richard Law, a top 23% analyst from Goldman Sachs upgrades PTGX to a strong buy rating and raises their PTGX price target from $110.00 to $186.00, on Aug 10, 2026.
Goldman Sachs's Richard Law upgraded their rating on Protagonist Therapeutics (NASDAQ: PTGX) from Hold to Strong Buy on 2026/08/10. The analyst also raised their price target by 69.1% from $110 to $186.
Protagonist Therapeutics reported its Q2 2026 earnings.
Upgrading the stock and raising their price target ahead of the Phase 2 readout, Law opined that because of the favorable Phase 1 profile and in vitro potency comparable to Bimzelx's option, Protagonist Therapeutics' PN-881 could deliver efficacy within Bimzelx's efficacy range in various inflammatory diseases but with oral advantages similar to Icotyde.
Looking ahead, the analyst said that Icotyde's blockbuster potential suggests that an oral IL-17 with Bimzelx-like efficacy could have "substantial commercial potential and attract multiple partnership interests."
Earnings Report
For Q2 2026, Protagonist Therapeutics reported:
- EPS of $2.29, which beat the Zacks Consensus Estimate of $2.11 and Q2 2025's $(0.55).
- Revenue of $213.48M, which missed the Zacks Consensus Estimate by 3.12% but beat Q2 2025's $5.55M
Management did not provide financial guidance in its press release.
President & CEO Dinesh V. Patel commented: "The second quarter of 2026 marked a defining growth phase for Protagonist with a successful commercial launch of ICOTYDE through our strategic partner and accelerating momentum across our internal R&D pipeline.
"ICOTYDE is quickly becoming a paradigm-shifting oral therapy for patients with moderate-to-severe plaque psoriasis, and rusfertide is approaching an FDA decision that could establish it as a first-in-class erythrocytosis targeted medicine for patients with polycythemia vera.
"Equally exciting is the decision to advance our wholly owned oral IL-17 antagonist PN-881 into a comprehensive Phase 2b psoriasis program, based on the strongly supportive pharmacokinetic results from the Phase 1 study.
"Behind PN-881, we have a maturing set of diverse assets moving toward clinical studies in obesity, hematology and immunology.
"These are the results of years of disciplined investment in differentiated science and mark the beginning, not the culmination, of a new phase of value creation as we continue to advance our peptide platform and clinical pipeline."
Jonathan Wolleben, a top 2% analyst from Citizens maintains PTGX with a buy rating and raises their PTGX price target from $120.00 to $137.00, on May 6, 2026.
Kaveri Pohlman, a top 15% analyst from Clear Street maintains PTGX with a strong buy rating and raises their PTGX price target from $104.00 to $116.00, on Apr 7, 2026.
You can dig deeper into what analysts are projecting on the Protagonist Therapeutics stock forecast page.
PTGX Technical Indicators
PTGX Earnings
Last year, PTGX earnings were $82.91M. In the past two year, PTGX's earnings have grown by -34.84% per year. This was slower than the Biotechnology industry average of 9.9%.
Last year, PTGX revenue was $281.99M. During the last 5 year, PTGX's revenue has gone up by 59.62% per year. This was faster than the Biotechnology industry average of 24.78%.
Dive into PTGX's earnings and revenue performance here.
What are PTGX insiders up to?
Over the last year, insiders at PTGX have sold more shares than they have bought.
Dinesh V. Ph D. Patel, CEO;Pres of PTGX, was the latest PTGX insider to buy. They bought $157,059.24 worth of PTGX shares on Sep 10, 2026.
Learn more about who owns PTGX stock here.
Does PTGX provide a stable income stream?
No, Protagonist Therapeutics doesn't provide an income stream by paying out dividends.
Get analysis from other traders
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other traders have to say.
Step 5: Make your PTGX buy order
You have two main options:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are usually sufficient. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific dollar amount, use a limit order.
Press the Open Trade button and your broker will place the order.
If you need additional assistance buying stocks on eToro, watch the helpful video below:
Step 6: Keep an eye on your PTGX investment
Now that you own some PTGX shares, you'll want to keep up with your new investment.
Create a watchlist to track your PTGX stock.
PTGX Feed
How to Buy Stock in Protagonist Therapeutics
To summarize, here are the 6 steps for buying Protagonist Therapeutics stock:
- Figure out where to buy Protagonist Therapeutics stock
- Open your brokerage account
- Put funds into your investment account
- Analyze Protagonist Therapeutics stock
- Make your PTGX buy order
- Keep an eye on your PTGX investment
If you are looking for a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to keep track of your investment in Protagonist Therapeutics, click below.
Related Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.